The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)
Editorial
Clinical outcome after interventions with paclitaxel-coated balloons: a PCR statement
Alexandra Lansky1,2, MD; Alberto Cremonesi3, MD; Bruno Scheller4, MD; Stefan James5, MD; Daniel Grubman1, BA; Jean Fajadet6, MD; Antoine Sauguet6, MD; Antonio Micari7,8, MD; Giovanna Sarno5, MD; Marc Bosiers9,10, MD; Andreas Baumbach1,2, MD; William Wijns11, MD
1. Yale University School of Medicine, New Haven, CT, USA; 2. Barts Heart Centre, London and Queen Mary University of London, London, United Kingdom; 3. Department of Cardiology, Maria Cecilia Hospital - GVM Care & Research, Cotignola, Italy; 4. Clinical and Experimental Interventional Cardiology, University of Saarland, Homburg/Saar, Germany; 5. Department of Medical Science, Cardiology, Uppsala University, Uppsala, Sweden; 6. Interventional Cardiology, Clinique Pasteur, Toulouse, France; 7. Maria Cecilia Hospital, Cotignola, Italy; 8. Cardiology and Cardiovascular Department, Humanitas Gavazzeni Hospital, Bergamo, Italy; 9. Department of Vascular Surgery, AZ Sint Blasius, Dendermonde, Belgium; 10. Foundation for Cardiovascular Research and Education, Münster, Germany; 11. The Lambe Institute for Translational Medicine and Curam, National University of Ireland, Galway and Saolta University Healthcare Group, Galway, Ireland
Paris Course on Revascularisation (PCR) statements are intended to represent a practical perspective from the PCR community representing a constituency of ≈60,000 active members on areas of relevant practice based on informed review of evidence and prevailing clinician interpretation. The PCR statement on paclitaxel drug-coated balloon (DCB) use in peripheral interventions was presented at EuroPCR 2019 (Paris, France) to address the ongoing controversy raised by the meta-analysis published in the Journal of the American Heart Association (JAHA). The meta-analysis prompted widespread concern by suggesting that treatment of patients with superficial femoropopliteal artery (SFA) disease using paclitaxel-coated devices (stents or DCBs) ...
Sign in to read and download the full article
Forgot your password? No account yet?
Sign up for free!
Create my pcr account Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com
Read next article
Involving the patient’s perspective and preferences concerning coronary angiography and percutaneous coronary intervention
Latest news
AHEAD OF PRINT
Catheter-directed thrombolysis in intermediate-high risk acute pulmonary embolism
FREE ARTICLE - Josef Kroupa et al
May 27, 2022
EUROPCR LATE BREAKING
EuroPCR 2022 Late-breaking publications: watch the interviews with the authors!
May 23, 2022
NEW ISSUE
TAVI vs SAVR for bicuspid anatomies; PVR and TAVI; LAA thrombus trapping; crush techniques for bifurcation PCIs; stent elongation in POT and more
May 18, 2022
AHEAD OF PRINT
Delayed hospitalisation in the MITRA-FR trial
FREE ARTICLE - Guillaume Leurent et al
May 25, 2022
AHEAD OF PRINT
Complete cerebral protection during TAVI
FREE ARTICLE - Dariusz Jagielak et al
May 24, 2022
AHEAD OF PRINT
Outcomes of PCI for stent thrombosis
FREE ARTICLE - Mohamed O. Mohamed et al
May 24, 2022
EUROPCR LATE BREAKING
Changes in voice patterns for monitoring heart failure deterioration
FREE ARTICLE - Chaim Lotan et al
May 24, 2022